EyePoint Advances DURAVYU Phase 3 Wet AMD Program

EyePoint Pharmaceuticals ( (EYPT) ) just unveiled an announcement.

On May 14, 2026, EyePoint reported that an independent Data Safety Monitoring Committee issued a third consecutive positive recommendation for its pivotal Phase 3 wet AMD program evaluating DURAVYU, allowing the LUGANO and LUCIA trials to continue without protocol changes. As of May 2, 2026, all active treatment-arm patients had received a second dose at Week 32, over 35% had received a third dose at Week 56, and interim masked data showed a safety profile consistent with four earlier trials involving more than 190 patients.

The fully enrolled LUGANO and LUCIA studies, which randomize more than 900 patients to either DURAVYU every six months or on-label aflibercept, are designed as non-inferiority trials with topline data expected to begin in mid-2026. If ultimately successful, the positive safety momentum and the program’s focus on 6‑month redosing could position DURAVYU as a first- and potentially best-in-class sustained-release therapy in wet AMD, reducing treatment burden and potentially strengthening EyePoint’s competitive standing in the high-value retinal disease market.

The most recent analyst rating on (EYPT) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.

Spark’s Take on EYPT Stock

According to Spark, TipRanks’ AI Analyst, EYPT is a Neutral.

The score is held down primarily by weak financial performance (sharp revenue drop, large losses, and significant cash burn). Offsetting this, the earnings call points to strong clinical progress and near-term pivotal catalysts with stated runway into Q4 2027, while technicals remain mixed-to-weak and valuation is constrained by negative earnings and no dividend.

To see Spark’s full report on EYPT stock, click here.

More about EyePoint Pharmaceuticals

EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for serious retinal diseases, with a lead product candidate, DURAVYU, an investigational sustained-delivery vorolanib treatment using the company’s proprietary Durasert E technology. The Massachusetts-based company targets major retinal indications such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), and operates a commercial manufacturing facility supporting its late-stage pipeline.

Average Trading Volume: 1,275,889

Technical Sentiment Signal: Buy

Current Market Cap: $1.14B

See more data about EYPT stock on TipRanks’ Stock Analysis page.